# A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted

> **NCT03547245** · PHASE1 · COMPLETED · sponsor: **International AIDS Vaccine Initiative** · enrollment: 46 (actual)

## Conditions studied

- HIV/AIDS

## Interventions

- **BIOLOGICAL:** eOD-GT8 60mer + AS01B/ DPBS sucrose/IM
- **BIOLOGICAL:** eOD-GT8 60mer + AS01B/ DPBS sucrose/IM
- **BIOLOGICAL:** DPBS Sucrose

## Key facts

- **NCT ID:** NCT03547245
- **Lead sponsor:** International AIDS Vaccine Initiative
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-15
- **Primary completion:** 2020-01-17
- **Final completion:** 2021-08-13
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2022-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03547245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03547245, "A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03547245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*